This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cannon, C. P. Search for Related Content PubMed PubMed Citation Articles by Cannon, C. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Arterial thrombosis Platelet function inhibitors Catheter-based coronary interventions: stents Acute coronary syndromes Related Article

(Circulation. 2002;106:1588.)
© 2002 American Heart Association, Inc.

Editorial

Evidence-Based Risk Stratification to Target Therapies in Acute Coronary Syndromes

Christopher P. Cannon, MD

From the TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.

Correspondence to Christopher Cannon, MD, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail cpcannon@partners.org

Key Words: Editorials • angina • myocardial infarction • catheterization • anticoagulants

An extract of the first 250 words of the full text is provided, because this article has no abstract.

With the ever-increasing number of new treatments for the wide spectrum of patients with acute coronary syndromes (ACS), risk stratification has become the centerpiece of initial evaluation for these patients.¹ The overriding principle is to target more aggressive antithrombotic and interventional therapies in patients at higher risk.^1,2

See p 1622

The approach to risk stratification has evolved during the past 2 decades from a practice that once involved an evaluation for residual ischemia and for left ventricular dysfunction after myocardial infarction (MI). However, risk stratification has now evolved more to include assessment of the risk of future cardiac events, which can be predicted on the basis of clinical features at the time of the initial assessment in the emergency department. This change in timing parallels the change in nomenclature of ACS from Q-wave/non–Q wave MI to ST-elevation MI (STEMI) versus non-STEMI, a change that was made necessary by the need to make immediate treatment decisions about reperfusion therapy for those with ST elevation (and not for those without ST elevation).² Similarly, risk stratification is now performed immediately (not days later) to assist in decisions on appropriate initial therapy and triage.

This notion of immediate risk assessment was first proposed in the 1994 unstable angina guidelines,³ and is now strongly evidence based, with numerous studies supporting the need to target the newer antithrombotic and interventional therapies to higher-risk ACS patients.^4–18 Thus, risk stratification is key to the initial evaluation of patients with ACS because physicians will treat patients differently on the . . . [Full Text of this Article]

Related Article:

Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups

Andrzej Budaj, Salim Yusuf, Shamir R. Mehta, Keith A.A. Fox, Gianni Tognoni, Feng Zhao, Susan Chrolavicius, David Hunt, Matyas Keltai, Maria Grazia Franzosi for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators
Circulation 2002 106: 1622-1626. [Abstract] [Full Text]

This article has been cited by other articles:

				E. S. Brilakis, A. F. Hernandez, D. Dai, E. D. Peterson, S. Banerjee, G. C. Fonarow, C. P. Cannon, and D. L. Bhatt Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease: Results From the Get With the Guidelines Program Circulation, August 18, 2009; 120(7): 560 - 567. [Abstract] [Full Text] [PDF]

				D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18 Eur. Heart J., May 1, 2008; 29(9): 1096 - 1102. [Abstract] [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]

				A. O. Adesanya, J. A. de Lemos, N. B. Greilich, and C. W. Whitten Management of perioperative myocardial infarction in noncardiac surgical patients. Chest, August 1, 2006; 130(2): 584 - 596. [Abstract] [Full Text] [PDF]

				J. W. Ryan, E. D. Peterson, A. Y. Chen, M. T. Roe, E. M. Ohman, C. P. Cannon, P. B. Berger, J. F. Saucedo, E. R. DeLong, S.-L. Normand, et al. Optimal Timing of Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry Circulation, November 15, 2005; 112(20): 3049 - 3057. [Abstract] [Full Text] [PDF]

				A. Elsasser and C. W. Hamm Percutaneous coronary intervention guidelines: new aspects for the interventional treatment of acute coronary syndromes Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K5 - K9. [Abstract] [Full Text] [PDF]

				S J Walsh, M S Spence, D Crossman, and A A J Adgey Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond Heart, September 1, 2005; 91(9): 1135 - 1140. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]

				C. Cannon Revascularization for everyone?: reply Eur. Heart J., March 1, 2005; 26(5): 525 - 525. [Full Text] [PDF]

				C. P. Cannon Revascularization for everyone?: reply Eur. Heart J., January 2, 2005; 26(2): 201 - 201. [Full Text] [PDF]

				J. M. Abadie, C. L. Blassingame, and D. D. Bankson Albumin Cobalt Binding Assay to Rule Out Acute Coronary Syndrome Ann. Clin. Lab. Sci., January 1, 2005; 35(1): 66 - 72. [Abstract] [Full Text] [PDF]

				D. J. Kereiakes Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation Circulation, October 21, 2003; 108(90161): III-22 - 27. [Abstract] [Full Text] [PDF]

				D. A. Morrow, N. Rifai, M. S. Sabatine, S. Ayanian, S. A. Murphy, J. A. de Lemos, E. Braunwald, and C. P. Cannon Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes Clin. Chem., August 1, 2003; 49(8): 1396 - 1398. [Full Text] [PDF]

				D. A. Morrow, J. A. de Lemos, M. S. Sabatine, and E. M. Antman The Search for a Biomarker of Cardiac Ischemia Clin. Chem., April 1, 2003; 49(4): 537 - 539. [Full Text] [PDF]

				Clopidogrel Benefits a Range of ACS Risk Groups Journal Watch Cardiology, November 29, 2002; 2002(1129): 6 - 6. [Full Text]